Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)-Reference-Cited by-同舟云学术

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

Published:2017-11 Issue:11 Volume:28 Page:2698-2706
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Nokihara H.,Lu S.,Mok T.S.K.,Nakagawa K.,Yamamoto N.,Shi Y.K.,Zhang L.,Soo R.A.,Yang J.C.,Sugawara S.,Nishio M.,Takahashi T.,Goto K.,Chang J.,Maemondo M.,Ichinose Y.,Cheng Y.,Lim W.T.,Morita S.,Tamura T.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/11/2698/24168883/mdx419.pdf

Reference11 articles.

1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

5. Individual patient data meta-analysis of docetaxel administered once every 3weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer;Di Maio;J Clin Oncol,2007

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib plus oral fluoropyrimidine S-1 in treating patients with refractory or relapsed small-cell lung cancer (SALTER TRIAL): an open-label, multicenter, single-arm, phase II trial;2024-06-07

2. Influence of Previous Therapy for Neutropenia Caused by Combination Therapy of Ramucirumab and Docetaxel;Cancers;2024-05-30

3. Advances in monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer: a narrative review;Translational Cancer Research;2024-04

4. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial;Lung Cancer;2024-03

5. Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer;Cancers;2023-11-21